Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
212Pb-PS0001
- Development stage
- Preclinical
- Lead developer
- Advancell
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
212Pb-PS0001 is a targeted alpha therapy (TAT) radiopharmaceutical developed by AdvanCell for the treatment of prostate cancer. It consists of the alpha-emitting radioisotope lead-212 (212Pb) conjugated to a high-affinity ligand that specifically targets the prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II or FOLH1. PSMA is a well-validated target that is significantly overexpressed in prostate cancer cells, particularly in metastatic castration-resistant prostate cancer (mCRPC). Upon administration, 212Pb-PS0001 binds to PSMA-expressing tumor cells and delivers high-linear-energy-transfer (LET) alpha radiation, which induces lethal double-strand DNA breaks and potent cytotoxicity with minimal damage to surrounding healthy tissue. In addition to its direct anti-tumor activity, 212Pb-PS0001 is being studied for its potential to modulate the tumor microenvironment and induce a systemic anti-tumor immune response.
- Other names
- 212Pb-PSMA
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 212Pb-PS0001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 212Pb-PS0001.